The concept that individuals with the same disease and a similar clinical presentation may
have very different outcomes and need very different therapies is not novel. With the …

Treatment of acute rejection (AR) following kidney transplantation has improved in recent
years, but there are still limitations to successful outcomes. This review article covers …

The current immunosuppressive pipeline in kidney transplantation is limited. In part, this is
due to excellent one-year allograft outcomes with the current standard of care (ie …

The importance of genetic and biochemical variation in renal transplant outcomes has been
clear since the discovery of the HLA in the 1950s. Since that time, there have been huge …

Detecting acute rejection in kidney transplantation has been traditionally done using
histological analysis of invasive allograft biopsies, but this method carries a risk and is not …

Background and objectives Acute rejection is a significant complication detrimental to kidney
transplant function. Current accepted means of diagnosis is percutaneous renal biopsy, a …

While advances in patient care and immunosuppressive pharmacotherapies have increased
the lifespan of heart allograft recipients, there are still significant comorbidities post …

Background Although improved understanding and assessment of organ rejection
significantly contribute to long-term allograft survival after kidney transplantation, reliable …

One important use of genome-wide transcriptional profiles is to identify relationships
between transcription levels and patient outcomes. These translational insights can guide …

This review is focused on present and future biomarkers, along with pharmacogenomics
used in clinical practice for kidney transplantation. It aims to highlight biomarkers that could …